R h i n o s c l e r o m a is a chronic granulomatous disease involving upper respiratory tract caused by Klebsiella rhinoscleromatis. Historically, disease was first diagnosed in 1870 by Von Hebra. He also coined the term Rhinoscleroma (Rhino-nose; Scleroma-hard). Frisch in 1877, discovered the bacilli Klebsiella rhinoscleromatis which was named after him. Following this disease was reported in many countries world all over. Eastern Europe, North and central Africa, Southern Asia, Middle East and central America. Rhinoscleroma is endemic in Egypt. Rhinoscleroma is more common in people belonging to low economic strata and living in unsanitary condition. Thus this disease is also known as the Disease of Great Unwashed"1. In India, it is endemic in Madhya Pradesh, Uttar Pradesh, Rajasthan and above an imaginary line joining Bombay and Vishakhapatnam 2. Granuloma formed results in deformity and disfigurement. Some times cicatric stenosis of airway may results in the death of the patients. Frisch bacilli or Klebsiella rhinoscleromatis is a coil form Gram Negative bacilli which have mucopolysaccharide capsule, This capsule protects the bacilli from antibiotics and host antibodiesL All the available therapeutic modalities including chemicals, radiation, surgery and antibiotics were tried in hope to cure the disease 4. Many antibiotics including streptomycin, chlorom)~cetin, tetracycline 5, cephalosporins 6, ceforizanide', clofazimin 8 and recently Rifampcin 9,1~ has been tried. Cure rate achieved was high with some of the antibiotics but they also have high recurrence rate. Also all these drugs are required to be given for long duration and carried their own side effects beside being costly. This requires continuous monitoring of patients and thus add to the cost of treatment. This restricted their use in already poor patient. We undertook this study in search of a long standing, cost effective and safe remedy for Rhinoscleroma.
Materials and Methods
This study was undertaken at Department of Otorhinolaryngology, G.R. Medical College and Jaya Arogya Group of Hospitals, Gwalior, where about 26 cases in different stages of Rhinoscleroma were studied. Detail history was taken and comphrensive clinical examination was done. Diagnosis was confirmed by excision biopsy and histopathological examination.
These cases of Rhinoscleroma were given acriflavin ointment in the concentration of 1%, 2% and 5%. Acriflavin was locally applied for about 8 weeks. During this period serial histopathological sections were also studied. After regression of disease patients were followed up to 6 months clinically as well as histopathologically. Cases which showed poor response were also given acriflavin for 4 weeks more.
Acriflavin is orange coloured compound which belongs to acridine family of antiseptic agents. This is used by surgeons for bladder washing and cleaning of abscess cavities. Also microbiologist used acriflavin for study of malaria parasites.
Observation
In this sutdy 26 diagnosed cases belonging to age group of 19 to 60 years of age were taken. Male preponderance was seen with 20 of the 26 cases belonging to male sex. All the cases belong to low socio-economic status and inhabited in poor sanitary conditions. Out of 26 cases, 2 were in atrophic stage and 10 were in granulomatous stage. Involvement of upper lip was seen in 2 cases while 1 had granuloma over cheek without any sign of nasal involvement. In two cases, even cicatrisation of pharyngeal and nasopharyngeal mucosa was seen. One case had dyspnoea due to laryngeal stenosis and required tracheostomy (Table I) . 
Results
Acriflavin, an antiseptic, was used in the form of lotion for local application (Table I1) . On follow up one percentage acriflavin was found to be useful on atrophic stage with partial response seen in cases with granulomas. These cases were then given 2 percent acriflavin. Two percent acriflavin was given to 20 cases in all.
Of which 4 cases received one percent acriflavin and two cases 5% acriflavin for 2 weeks. After therapy of 8 weeks 14 cases showed total regression of disease and 3 cases showed partial regression of disease and required prolong therapy (Table III) .
Six cases of cicatric stage received 5% acriflavin and showed good response. Two of these cases complaint of excessive burning, crusting and bleeding per nose. These cases though showing good response were changed to two percent acriflavin. Remaining 4 cases got cured with 5% acriflavin. In two cases with extensive cicatrisation, surgical excision was also performed prior to acriflavin therapy, One case expired during 4th week of the course of treatment. While two cases after 5th and 7th week of treatment didn't turn up for follow up and thus all three were categorily kept in cases showing partial response. On six month of follow up none of the case showed recurrence. The 3 cases which showed partial response, on continuation of therapy for another 4 weeks got cured and on follow up showed no recurrence. Over all cure rate after 8 weeks of therapy was 77.78% with 11% showing partial response, while cure rate was 100% after 12 weeks excluding cases lost during follow up.
Discussion
Treatment of scleroma has always been an enigma for otolaryngologists. Where search for long lasting, cost effective therapy is still going on. Every available
